73 results
424B5
TRML
Tourmaline Bio Inc
26 Jan 24
Prospectus supplement for primary offering
4:08pm
of death globally. Preventing major adverse cardiovascular events (“MACE”), such as death, nonfatal myocardial infarction or nonfatal stroke, has
424B5
TRML
Tourmaline Bio Inc
24 Jan 24
Prospectus supplement for primary offering
9:20pm
. Atherosclerotic cardiovascular disease (“ASCVD”) is a leading cause of death globally. Preventing major adverse cardiovascular events (“MACE … ”), such as death, nonfatal myocardial infarction or nonfatal stroke, has the potential to significantly reduce global cardiovascular disease burden. IL-6 has been
8-K
EX-99.1
0jojdkni
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.2
0dpd yczv
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
mfg44a6 sv
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
lbislcj
27 Oct 23
Departure of Directors or Certain Officers
5:17pm
8-K
EX-10.1
ak313nmnui ttuu
27 Oct 23
Departure of Directors or Certain Officers
5:17pm
8-K
EX-10.7
of5 kqsuroflcpebu
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.8
jvbr4vdafojw
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.3
l0ykan4
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
qnwzkzg44
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.2
ywaov
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-99.1
kmskico
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.4
se86egau98ae849wxy
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
425
1b5wub
26 Sep 23
Business combination disclosure
8:24am